Piper Jaffray is out with its report today on Regeneron Pharmaceuticals REGN, reiterating Overweight.
In a note to clients, Piper Jaffray writes, "We reiterate our Overweight rating and $62 target based on a proj. enterprise value of $5.26 billion. We add mid-12E cash of $311 million. Regeneron has no debt."
Shares of REGN closed Friday at $54.58, down 2.13% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBiotechnologyHealth CarePiper JaffrayRegeneron Pharmaceuticals
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in